Shattuck Labs Inc (NAS:STTK)

$ 7.24 -0.09 (-1.23%) Market Cap: 344.27 Mil Enterprise Value: 236.98 Mil PE Ratio: 0 PB Ratio: 2.67 GF Score: 66/100

Shattuck Labs Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Shattuck Labs Inc Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline HR-MDS and TP53m AML and Review of Dose-Escalation Data from ASH 2023 Annual Meeting Transcript
Dec 13, 2023
Q3 2023 Shattuck Labs Inc Earnings Call Transcript
Nov 09, 2023

$1.82 (-23.21%)

Earnings
Shattuck Labs Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Shattuck Labs Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Q4 2022 Shattuck Labs Inc Earnings Call Transcript
Feb 23, 2023

$4.54 (+4.37%)

Earnings
Shattuck Labs Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Shattuck Labs Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Shattuck Labs Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 29, 2022
Shattuck Labs Inc at Cowen IO Next Summit (Virtual) Transcript
Nov 11, 2022
Q3 2022 Shattuck Labs Inc Earnings Call Transcript
Nov 08, 2022

$2.21 (-6.75%)

Earnings
Shattuck Labs Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Shattuck Labs Inc at Citi BioPharma Conference Transcript
Sep 08, 2022
Shattuck Labs Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 11, 2022
Shattuck Labs Inc To Discuss Highlighting Data Presented at the 2021 SITC Annual Meeting Call Transcript
Nov 12, 2021
Q2 2021 Shattuck Labs Inc Earnings Call Transcript
Aug 11, 2021

$20.05 (-1.38%)

Earnings
Shattuck Labs Inc at Truist Securities Life Sciences Summit (May Series) Transcript
May 05, 2021
Shattuck Labs Inc Present at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2021

Shattuck Labs Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 11, 2022 / 05:30PM GMT

Release Date Price: $3.8 (-3.55%)

Transcript

Gil Blum

Needham & Company, LLC - Analyst

My name is Gil Blum and I'm a Senior Biotech Analyst here at Needham & Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Shattuck's management team, including Taylor Schreiber, CEO; and Andrew Neill, the Chief Financial Officer. As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask A Question box, below the video feed window.

So to kind of start things off, maybe it's worth reminding our audience of Shattuck's key technology, which is these agonist redirected checkpoints, which are dual-targeting molecules with unique structural properties. So maybe describe one of these for us and how it's different compared to existing therapeutics, let's say, small molecules and antibodies.

Taylor Schreiber

Shattuck Labs, Inc. - CEO & Co-Founder

Sure. Well, Gil, thank you for having us, and thanks to Needham. It's our pleasure to present at the fireside chat with you today. And so to start off

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.